Over the past few decades, advances in pharmacological, catheter-based, and surgical
reperfusion have improved outcomes for patients with acute myocardial infarctions …

Venoarterial extracorporeal membrane oxygenation provides cardiorespiratory support to
patients in cardiogenic shock. This comes at the cost of increased left ventricle (LV) afterload …

Background Extracorporeal life support (ECLS) is increasingly used in the treatment of
infarct-related cardiogenic shock despite a lack of evidence regarding its effect on mortality …

Background Venoarterial extracorporeal membrane oxygenation (VA-ECMO) increases left
ventricular (LV) afterload, potentially provoking LV distention and impairing recovery. LV …

Background Venoarterial extracorporeal membrane oxygenation (VA-ECMO) is increasingly
used in patients with cardiogenic shock despite the lack of evidence from adequately …

Cardiogenic shock accounts for~ 100,000 annual hospital admissions in the United States.
Despite improvements in medical management strategies, in-hospital mortality remains …

Aim The management of cardiogenic shock remains a clinical challenge even in well‐
developed healthcare systems, best illustrated by its high mortality despite numerous …

Originally intended for life-saving salvage therapy, the use of temporary mechanical
circulatory support (MCS) devices has become increasingly widespread in a variety of …

Background It is currently unclear if active left ventricular (LV) unloading should be used as
a primary treatment strategy or as a bailout in patients with cardiogenic shock (CS) treated …

The Impella device (Impella, Abiomed, Danvers, MA) is a percutaneous transvalvular
microaxial flow pump that is currently used for (1) cardiogenic shock,(2) left ventricular …